M.D., Chief Medical Officer of Werew - Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and ...

In a challenging turn for Werewolf Therapeutics, the biotechnology firm's stock has plummeted to a 52-week low, trading at $1.37, ...

After hours: March 21 at 7:37:58 PM EDT Loading Chart for HOWL ...

Pre-Market: 8:40:24 a.m. EDT Loading Chart for HOWL ...

After hours: 21 March at 19:37:58 GMT-4 Loading Chart for HOWL ...